. 2022 Jun;23(6):748-757.

doi: 10.1016/S1470-2045(22)00202-9. Epub 2022 May 23.

VSports手机版 - Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study

Lennard Y W Lee¹, Thomas Starkey², Maria C Ionescu³, Martin Little⁴, Michael Tilby⁵, Arvind R Tripathy⁵, Hayley S Mckenzie⁶, Youssra Al-Hajji⁷, Matthew Barnard³, Liza Benny³, Alexander Burnett⁸, Emma L Cattell⁹, Jackie Charman¹⁰, James J Clark¹¹, Sam Khan¹², Qamar Ghafoor⁵, George Illsley³, Catherine Harper-Wynne¹³, Rosie J Hattersley¹⁴, Alvin J X Lee¹⁵, Pauline C Leonard¹⁶, Justin K H Liu¹⁷; NCRI Consumer Forum; Matthew Pang¹⁸, Jennifer S Pascoe⁵, James R Platt¹⁷, Vanessa A Potter¹⁹, Amelia Randle²⁰, Anne S Rigg²¹, Tim M Robinson²², Tom W Roques²³, René L Roux⁴, Stefan Rozmanowski¹⁸, Mark H Tuthill⁴, Isabella Watts²⁴, Sarah Williams⁵, Tim Iveson²⁵, Siow Ming Lee²⁶, Gary Middleton²⁷, Mark Middleton²⁸, Andrew Protheroe⁴, Matthew W Fittall²⁹, Tom Fowler³, Peter Johnson³⁰

Collaborators, Affiliations

Collaborators

NCRI Consumer Forum:
Emma Kinloch, Emily Lam, Gillian Murphy, Malcolm Rhodes, Kate Robinson

"V体育ios版" Affiliations

¹ Department of Oncology, University of Oxford, Oxford, UK; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. Electronic address: lennard.lee@www.qiuluzeuv.cn.
² Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
³ UK Health Security Agency, London, UK.
⁴ Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
⁵ Department of Oncology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
⁶ Oncology Department, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
⁷ Birmingham Medical School, University of Birmingham, Birmingham, UK.
⁸ NHS England, London, UK; NHS Improvement, London, UK.
⁹ Department of Cancer, Taunton and Somerset NHS Foundation Trust, Taunton, UK.
¹⁰ National Disease Registration Service, NHS Digital, London, UK.
¹¹ Department of Surgery and Cancer, Imperial College London, London, UK.
¹² Leicester Cancer Research Centre, University of Leicester, Leicester, UK.
¹³ Kent Oncology Centre, University of Kent and Kent and Medway Medical School, Maidstone, UK.
¹⁴ Department of Oncology, Torbay Hospital NHS Foundation Trust, Torquay, UK.
¹⁵ UCL Cancer Institute, University College London Hospitals NHS Trust and University College London, London, UK.
¹⁶ Cancer Services, Barking, Havering and Redbridge University Hospitals NHS Trust, Romford, UK.
¹⁷ Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.
¹⁸ Department of Health and Social Care, London, UK.
¹⁹ Department of Oncology, University Hospital Coventry and Warwickshire, Coventry, UK.
²⁰ Royal College of Physicians, London, UK.
²¹ Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
²² Population Health Sciences, University of Bristol, Bristol, UK.
²³ Cancer Services, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK.
²⁴ Department of Academic Oncology, Royal Free Hospital, London, UK.
²⁵ Cancer Sciences, University of Southampton, Southampton, UK.
²⁶ UCL Cancer Institute, University College London Hospitals NHS Trust and University College London, London, UK; CRUK Lung Cancer Centre of Excellence, University College London Hospitals NHS Trust and University College London, London, UK.
²⁷ Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK; Department of Oncology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
²⁸ Department of Oncology, University of Oxford, Oxford, UK.
²⁹ Cancer Services, The Royal Marsden NHS Foundation Trust, London, UK.
³⁰ NHS England, London, UK; Cancer Sciences, University of Southampton, Southampton, UK.

PMID: 35617989
PMCID: PMC9126559
DOI: 10.1016/S1470-2045(22)00202-9

"VSports最新版本" Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study

Lennard Y W Lee et al. Lancet Oncol. 2022 Jun.

. 2022 Jun;23(6):748-757.

doi: 10.1016/S1470-2045(22)00202-9. Epub 2022 May 23.

Authors

Collaborators

NCRI Consumer Forum:
Emma Kinloch, Emily Lam, Gillian Murphy, Malcolm Rhodes, Kate Robinson

VSports app下载 - Affiliations

¹ Department of Oncology, University of Oxford, Oxford, UK; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. Electronic address: lennard.lee@www.qiuluzeuv.cn.
² Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
³ UK Health Security Agency, London, UK.
⁴ Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
⁵ Department of Oncology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
⁶ Oncology Department, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
⁷ Birmingham Medical School, University of Birmingham, Birmingham, UK.
⁸ NHS England, London, UK; NHS Improvement, London, UK.
⁹ Department of Cancer, Taunton and Somerset NHS Foundation Trust, Taunton, UK.
¹⁰ National Disease Registration Service, NHS Digital, London, UK.
¹¹ Department of Surgery and Cancer, Imperial College London, London, UK.
¹² Leicester Cancer Research Centre, University of Leicester, Leicester, UK.
¹³ Kent Oncology Centre, University of Kent and Kent and Medway Medical School, Maidstone, UK.
¹⁴ Department of Oncology, Torbay Hospital NHS Foundation Trust, Torquay, UK.
¹⁵ UCL Cancer Institute, University College London Hospitals NHS Trust and University College London, London, UK.
¹⁶ Cancer Services, Barking, Havering and Redbridge University Hospitals NHS Trust, Romford, UK.
¹⁷ Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.
¹⁸ Department of Health and Social Care, London, UK.
¹⁹ Department of Oncology, University Hospital Coventry and Warwickshire, Coventry, UK.
²⁰ Royal College of Physicians, London, UK.
²¹ Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
²² Population Health Sciences, University of Bristol, Bristol, UK.
²³ Cancer Services, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK.
²⁴ Department of Academic Oncology, Royal Free Hospital, London, UK.
²⁵ Cancer Sciences, University of Southampton, Southampton, UK.
²⁶ UCL Cancer Institute, University College London Hospitals NHS Trust and University College London, London, UK; CRUK Lung Cancer Centre of Excellence, University College London Hospitals NHS Trust and University College London, London, UK.
²⁷ Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK; Department of Oncology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
²⁸ Department of Oncology, University of Oxford, Oxford, UK.
²⁹ Cancer Services, The Royal Marsden NHS Foundation Trust, London, UK.
³⁰ NHS England, London, UK; Cancer Sciences, University of Southampton, Southampton, UK.

PMID: 35617989
PMCID: PMC9126559
DOI: 10.1016/S1470-2045(22)00202-9 (V体育官网)

Abstract (V体育官网)

Background: People with cancer are at increased risk of hospitalisation and death following infection with SARS-CoV-2 VSports手机版. Therefore, we aimed to conduct one of the first evaluations of vaccine effectiveness against breakthrough SARS-CoV-2 infections in patients with cancer at a population level. .

Methods: In this population-based test-negative case-control study of the UK Coronavirus Cancer Evaluation Project (UKCCEP), we extracted data from the UKCCEP registry on all SARS-CoV-2 PCR test results (from the Second Generation Surveillance System), vaccination records (from the National Immunisation Management Service), patient demographics, and cancer records from England, UK, from Dec 8, 2020, to Oct 15, 2021. Adults (aged ≥18 years) with cancer in the UKCCEP registry were identified via Public Health England's Rapid Cancer Registration Dataset between Jan 1, 2018, and April 30, 2021, and comprised the cancer cohort. We constructed a control population cohort from adults with PCR tests in the UKCCEP registry who were not contained within the Rapid Cancer Registration Dataset. The coprimary endpoints were overall vaccine effectiveness against breakthrough infections after the second dose (positive PCR COVID-19 test) and vaccine effectiveness against breakthrough infections at 3-6 months after the second dose in the cancer cohort and control population. V体育安卓版.

Findings: The cancer cohort comprised 377 194 individuals, of whom 42 882 had breakthrough SARS-CoV-2 infections. The control population consisted of 28 010 955 individuals, of whom 5 748 708 had SARS-CoV-2 breakthrough infections. Overall vaccine effectiveness was 69·8% (95% CI 69·8-69·9) in the control population and 65·5% (65·1-65·9) in the cancer cohort V体育ios版. Vaccine effectiveness at 3-6 months was lower in the cancer cohort (47·0%, 46·3-47·6) than in the control population (61·4%, 61·4-61·5). .

Interpretation: COVID-19 vaccination is effective for individuals with cancer, conferring varying levels of protection against breakthrough infections VSports最新版本. However, vaccine effectiveness is lower in patients with cancer than in the general population. COVID-19 vaccination for patients with cancer should be used in conjunction with non-pharmacological strategies and community-based antiviral treatment programmes to reduce the risk that COVID-19 poses to patients with cancer. .

Funding: University of Oxford, University of Southampton, University of Birmingham, Department of Health and Social Care, and Blood Cancer UK V体育平台登录. .

PubMed Disclaimer

Conflict of interest statement (VSports最新版本)

Declaration of interests We declare no competing interests.

Figures

**Figure 1**
Vaccine effectiveness over time after the second COVID-19 vaccine dose in the cancer cohort versus the control population The error bars represent 95% CIs.

**Figure 2**
Heatmap showing overall vaccine effectiveness after the second dose and the interaction of patient age, sex, and cancer diagnosis Grey boxes denote insufficient data; white boxes denote inapplicable sections.

**Figure 3**
Forest plot showing multivariable-corrected overall vaccine effectiveness among predefined cancer subgroups The error bars represent 95% CIs. Regression models were fitted for the clinically relevant covariates of age, sex, Index of Multiple Deprivation, and ethnicity.

**Figure 4**
Waterfall plot showing multivariable-corrected waning vaccine effectiveness at 3–6 months by key cancer subgroups The most common solid tumours and haematological malignancies according to Cancer Research UK are shown.

See this image and copyright information in PMC

Comment in

V体育官网入口 - COVID-19 vaccine effectiveness in patients with cancer: remaining vulnerabilities and uncertainties.
Kuderer NM, Lyman GH. Kuderer NM, et al. Lancet Oncol. 2022 Jun;23(6):693-695. doi: 10.1016/S1470-2045(22)00252-2. Epub 2022 May 23. Lancet Oncol. 2022. PMID: 35617990 Free PMC article. No abstract available.

References (VSports手机版)

1. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. - PMC - PubMed
1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–2615. - PMC - PubMed
1. Lee LYW, Cazier J-B, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395:1919–1926. - "VSports在线直播" PMC - PubMed
1. Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395:1907–1918. - V体育平台登录 - PMC - PubMed
1. Lee LYW, Cazier J-B, Starkey T, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020;21:1309–1316. - PMC - PubMed

Publication types

Actions (VSports最新版本)

MeSH terms

Actions
Actions
Actions (V体育ios版)
Actions (VSports注册入口)
Actions
VSports在线直播 - Actions
Actions
Actions
Actions
Actions
VSports最新版本 - Actions

Substances

Actions
"V体育平台登录" Actions

Supplementary concepts

Actions

"V体育官网入口" Grants and funding

LinkOut - more resources (V体育平台登录)

Full Text Sources
Medical
- MedlinePlus Health Information
"VSports" Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

"VSports注册入口" Save citation to file

"V体育平台登录" Email citation

"V体育平台登录" Add to Collections

Add to My Bibliography (VSports手机版)

Your saved search

Create a file for external citation management software

Your RSS Feed

VSports手机版 - Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study

Collaborators

"V体育ios版" Affiliations

"VSports最新版本" Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study

Authors

Collaborators

VSports app下载 - Affiliations

Abstract (V体育官网)

Conflict of interest statement (VSports最新版本)

Figures

Comment in

References (VSports手机版)

Publication types

MeSH terms

Substances

Supplementary concepts

"V体育官网入口" Grants and funding

LinkOut - more resources (V体育平台登录)

Full Text Sources

Medical

"VSports" Research Materials

Miscellaneous